Literature DB >> 18726068

In vivo growth-inhibition of Sarcoma 180 by an alpha-(1-->4)-glucan-beta-(1-->6)-glucan-protein complex polysaccharide obtained from Agaricus blazei Murill.

Maria Leônia Costa Gonzaga1, Daniel Pereira Bezerra, Ana Paula Negreiros Nunes Alves, Nylane Maria Nunes de Alencar, Rodney de Oliveira Mesquita, Michael Will Lima, Sandra de Aguiar Soares, Cláudia Pessoa, Manoel Odorico de Moraes, Letícia Veras Costa-Lotufo.   

Abstract

Agaricus blazei Murrill, a native mushroom of Brazil, has been widely consumed in different parts of the world due to its anticancer potential. This effect is generally attributed to its polysaccharides; however, the precise structure of these has not been fully characterized. To better understand the relationship between polysaccharide structures and antitumor activity, we investigated the effect of the intraperitoneally (i.p.) or orally (p.o.) administered alpha-(1-->4)-glucan-beta-(1-->6)-glucan-protein complex polysaccharide from A. blazei alone or in association with 5-fluorouracil (5-FU) in tumor growth using Sarcoma 180 transplanted mice. Hematological, biochemical, and histopathological analyses were performed in order to evaluate the toxicological aspects of the polysaccharide treatment. The polysaccharide had no direct cytotoxic action on tumor cells in vitro. However, the polysaccharide showed strong in vivo antitumor effect. Thus, the tumor growth-inhibitory effect of the polysaccharide is apparently due to host-mediated mechanisms. The histopathological analysis suggests that the liver and the kidney were not affected by polysaccharide treatment. Neither enzymatic activity of transaminases (AST and ALT) nor urea levels were significantly altered. In hematological analysis, leucopeny was observed after 5-FU treatment, but this effect was prevented when the treatment was associated with the polysaccharide. In conclusion, this polysaccharide probably could explain the ethnopharmacological use of this mushroom in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726068     DOI: 10.1007/s11418-008-0286-4

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  23 in total

1.  In vivo growth-inhibition of Sarcoma 180 by piplartine and piperine, two alkaloid amides from Piper.

Authors:  D P Bezerra; F O Castro; A P N N Alves; C Pessoa; M O Moraes; E R Silveira; M A S Lima; F J M Elmiro; L V Costa-Lotufo
Journal:  Braz J Med Biol Res       Date:  2006-06-02       Impact factor: 2.590

2.  Fractionation and antitumor activity of the water-insoluble residue of Agaricus blazei fruiting bodies.

Authors:  H Kawagishi; R Inagaki; T Kanao; T Mizuno; K Shimura; H Ito; T Hagiwara; T Nakamura
Journal:  Carbohydr Res       Date:  1989-03-15       Impact factor: 2.104

3.  Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model.

Authors:  Hiroshi Kobayashi; Ryuji Yoshida; Yasufumi Kanada; Yoichi Fukuda; Tatsuo Yagyu; Kiyokazu Inagaki; Toshiharu Kondo; Noriyuki Kurita; Mika Suzuki; Naohiro Kanayama; Toshihiko Terao
Journal:  J Cancer Res Clin Oncol       Date:  2005-05-10       Impact factor: 4.553

4.  Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in individual organs.

Authors:  N Takiguchi; N Saito; M Nunomura; K Kouda; K Oda; N Furuyama; N Nakajima
Journal:  Cancer Chemother Pharmacol       Date:  2001       Impact factor: 3.333

5.  Antitumor beta glucan from the cultured fruit body of Agaricus blazei.

Authors:  N Ohno; M Furukawa; N N Miura; Y Adachi; M Motoi; T Yadomae
Journal:  Biol Pharm Bull       Date:  2001-07       Impact factor: 2.233

6.  In-vitro and in-vivo antitumour activity of physalins B and D from Physalis angulata.

Authors:  Hemerson Iury Ferreira Magalhães; Maria Leopoldina Veras; Márcia Rocha Torres; Ana Paula Negreiros Nunes Alves; Otília Deusdênia Loiola Pessoa; Edilberto Rocha Silveira; Letícia Veras Costa-Lotufo; Manoel Odorico de Moraes; Cláudia Pessoa
Journal:  J Pharm Pharmacol       Date:  2006-02       Impact factor: 3.765

7.  Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions.

Authors:  Yoshiyuki Kimura; Tadashi Kido; Takeshi Takaku; Maho Sumiyoshi; Kimiye Baba
Journal:  Cancer Sci       Date:  2004-09       Impact factor: 6.716

8.  Piperine modulation of carcinogen induced oxidative stress in intestinal mucosa.

Authors:  A Khajuria; N Thusu; U Zutshi; K L Bedi
Journal:  Mol Cell Biochem       Date:  1998-12       Impact factor: 3.396

Review 9.  Mushrooms, tumors, and immunity: an update.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Exp Biol Med (Maywood)       Date:  2004-05

10.  Anti-tumor polysaccharide from the mycelium of liquid-cultured Agaricus blazei mill.

Authors:  M Mizuno; K Minato; H Ito; M Kawade; H Terai; H Tsuchida
Journal:  Biochem Mol Biol Int       Date:  1999-04
View more
  4 in total

Review 1.  Natural compounds for pediatric cancer treatment.

Authors:  Veronica Ferrucci; Iolanda Boffa; Gina De Masi; Massimo Zollo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-12-09       Impact factor: 3.000

2.  Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway.

Authors:  Yi Liu; Lingyun Zhang; Xiangxiang Zhu; Yuehua Wang; WenWei Liu; Wei Gong
Journal:  Immunology       Date:  2015-09-03       Impact factor: 7.397

3.  Agaricus subrufescens: A review.

Authors:  Komsit Wisitrassameewong; Samantha C Karunarathna; Naritsada Thongklang; Ruilin Zhao; Philippe Callac; Serge Moukha; Cyril Férandon; Ekachai Chukeatirote; Kevin D Hyde
Journal:  Saudi J Biol Sci       Date:  2012-01-14       Impact factor: 4.219

Review 4.  The Medicinal Values of Culinary-Medicinal Royal Sun Mushroom (Agaricus blazei Murrill).

Authors:  Hang Wang; Zhiming Fu; Chunchao Han
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-31       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.